1Rauchaus M,Doehner W,Francis DP,et al.Plasma cytokine parameters and mortality in patients with chronic heart failure[J].Ciculation,2000,102:3060-3067.
2Talwar S,Dowine PF,Squire IB,et al.An immunoluminometric assay for cardiotrophin-1.A newly identifiea cytokine is present in normal human plasma and is increased in CHF[J].Biochem Biophys Res Conmun,1999,261:567-571.
3Mann DL.Inflammatory mediators and the failing heart, past, present and the foreseeable future[J].Circ Rec,2002,91:988-998.
4Bozkurt B,Kribbs SB,Clubb Jr FJ,et al.Patho physiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats[J].Circulaction,1998,97:1382-1391.
5Kubota T,Hounoutas GS,Miyaglshima M,et al.Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy[J].Circulation,2000,101:2518-2525.
6Deswal A,Seta Y,Blosch CM,et al.A phase I trial of tumor necrosis factor receptor (P75) fusion protein (TNPR:Fc) in patients with advanced CHF[J].Circutation,1998,96:1323.
7Bozkurt B,Torre-Amione G,Soran O,et al.Results of a multidose phase I trial with tumor necrosis factor receptor(P75) fusion protein (Etanercept) in patients with heart failure (abstract)[J].J Am Coll Cardiol,1999,184A-SA.
8Krum H.Tumor nerosis factor-α blockade as a therapeutic strategy in CHF(RENEWAL and ATTACH):unsuccessful.tobe specific[J].J Cardial Failure,2002,8(6):365-368.
9Feldman AM,Kadokami T,Higuichi Y,et al.The role of anticytokine therapy in CHF:recent lessons from preclinical and clinical trial[J].J Med Clin N Am,2003,87:419-440.
10Boehm EA,Jones BE,Radda GK,et al.Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart[J].Am J Physiol Heart Circ Physiol,2001,280:H77-983.
